. Author manuscript; available in PMC: 2012 Dec 10.

Published in final edited form as: Nat Rev Clin Oncol. 2012 Feb 28;9(4):223–229. doi: 10.1038/nrclinonc.2012.21

Table 2.

Multivariable analysis of post-neoadjuvant tumor factors in P024 trial²²

Post-therapy factors	RFS		Breast cancer-specific survival

	HR (95% CI)	P	HR (95% CI)	P
Tumor stage (T1 or 2 vs T3 or 4)	2.8 (1.4–5.4)	0.003	4.4 (1.7–11.2)	0.002

Node status (+ versus −)	3.2 (1.5–6.9)	0.004	3.9 (1.1–13.7)	0.04

Ki-67 levels per 2.7-fold increase	1.3 (1.1–1.6)	0.003	1.4 (1.07–1.9)	0.01

ER, Allred score (0–2 versus 3–8)	2.8 (1.2–6.4)	0.02	7.0 (2.4–20.9)	<0.001

Abbreviations: ER, estrogen receptor; HR, hazard ratio; RFS, recurrence-free survival. Permission obtained from National Cancer Institute © Ellis, M. J. et al. J. Natl Cancer Inst. 100, 1380–1388 (2008).²²